Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies
Abstract
Objective To determine if respiratory syncytial virus (RSV) specific, serum antibody titers correlate with protection against RSV associated-hospitalization at all ages.Design Participants who were enrolled in a trial to determine the frequency of specific virus infections associated with hospitalization [J. Am. Med. Assoc. 283 (2000) 499] were included in our analysis if they were enrolled from July 1991 to June 1993, had a culture for virus isolation, and provided blood samples at hospitalization and 14-60 days later. RSV infection was defined by a positive culture and/or serology. Microneutralization, ELISA to the fusion (F) protein and Western blot were the serological assays that were used to determine correlates of immunity.Results One hundred and seventy-five individuals, 1 month to 89 years old, out of 538 patients hospitalized with an acute respiratory infection met the criteria for analysis. RSV associated-hospitalization occurred in 11 (40.7%) of 27 infants (<1 year), 8 (38.1%) of 21 young children (1 to <5 years), and 15 (11.8%) of 127 children and adults (> or =5 years). At the time of hospitalization, geometric mean neutralizing antibody titers (log(2)) to RSV/A and RSV/B, and geometric mean binding antibody titer (log(2)) to F protein were significantly higher in patients with non-RSV associated-hospitalization compared to those with RSV associated-hospitalization (RSV/A: 7.9 versus 6.1, P<0.001; RSV/B: 9.4 versus 7.3, P<0.001; ELISA-F, 13.9 versus 12.6, P=0.01). For every 1 log(2) increase in titer of neutralizing antibodies to RSV/A and RSV/B, and binding antibody to F protein there was a significant increase in the likelihood of not having an RSV associated-hospitalization by 22.3, 25, and 24.4% respectively. A minimal protective threshold titer of > or =6.0 (odds ratio 3.5; 95% CI 1.4-9.1) and > or =8.0 log(2) (odds ratio 2.9; 95% CI 1.1-7.7) against RSV associated-hospitalization was established for neutralizing antibodies to RSV/A and RSV/B; a threshold titer could not be established for binding antibody to F protein.Conclusion Participants with naturally acquired serum neutralizing antibody levels at least equal to the minimal protective threshold titer were approximately three times more likely not to have an RSV associated-hospitalization. We speculate that achieving a minimal protective threshold antibody titer through active immunization will significantly reduce RSV associated-hospitalization among all ages.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The neutralization titers elicited by LNP/RNA are above the titer of 380 that correlates with protection in cotton rats and similar to passively acquired serum neutralizing titers that correlate with protection of human infants from severe RSV disease.
“The neutralization titers elicited by LNP/RNA are above the titer of 380 that correlates with protection in cotton rats (30) and similar to passively acquired serum neutralizing titers that correlate with protection of human infants from severe RSV disease (31,32).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [32]
Cites
Bronchiolitis-Associated Hospitalizations Among US Children, 1980-1996
Shay, D. K. (1999) · JAMA · doi:10.1001/jama.282.15.1440 · Cited by 1,389 · see citing works
Glezen, W. P., Paredes, A., Allison, J. E., Taber, L. H., & Frank, A. L. (1981) · The Journal of Pediatrics · doi:10.1016/s0022-3476(81)80829-3 · Cited by 684 · see citing works
Impact of Respiratory Virus Infections on Persons With Chronic Underlying Conditions
Glezen, W. P. (2000) · JAMA · doi:10.1001/jama.283.4.499 · Cited by 558 · see citing works
Respiratory Syncytial Virus and Influenza A Infections in the Hospitalized Elderly
Falsey, A. R., Cunningham, C. K., Barker, W. H., Kouides, R. W., Yuen, J. B., Menegus, M. A., Weiner, L. B., Bonville, C. A., & Betts, R. F. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.2.389 · Cited by 371 · see citing works
Dankner, W. M. (1997) · Clinical Pediatrics · doi:10.1177/000992289703601013 · Cited by 313 · see citing works
Respiratory Syncytial Virus Pneumonia among the Elderly: An Assessment of Disease Burden
Han, L. L., Alexander, J. P., & Anderson, L. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/314567 · Cited by 302 · see citing works
Piedra, P. A., Grace, S. C., Jewell, A. M., Spinelli, S. H., BUNTING, D., HOGERMAN, D. A., Malinoski, F. J., & Hiatt, P. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199601000-00006 · Cited by 140 · see citing works
Self-citationFuture directions in vaccine prevention of respiratory syncytial virus
Piedra, P. A. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200205000-00038 · Cited by 16 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · see citing works
Swanson, K. A., Settembre, E. C., Shaw, C. A., Dey, A. K., Rappuoli, R., Mandl, C. W., Dormitzer, P. R., & Carfi, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106536108 · Cited by 285 · see citing works
Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190 · see citing works
Immunological Lessons from Respiratory Syncytial Virus Vaccine Development
Ruckwardt, T. J., Morabito, K. M., & Graham, B. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.007 · Cited by 185 · see citing works
Aliprantis, A. O., Shaw, C. A., Griffin, P., Farinola, N., Railkar, R. A., Cao, X., Liu, W., Sachs, J. R., Swenson, C. J., Lee, H., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1829899 · Cited by 149 · see citing works
Kulkarni, P. S., Hurwitz, J. L., Simões, E. A. F., & Piedra, P. A. (2018) · Viral Immunology · doi:10.1089/vim.2017.0147 · Cited by 53 · see citing works
Self-citation
- Authors
- Piedra, P.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Piedra, P
- ORCID
- Piedra, P
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2003-07-28
- Volume
- 21
- Issue
- 24
- Pages
- 3479-3482
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W1988930241
- Cited by
- 229
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 11 · 2023: 7 · 2022: 12 · 2021: 13 · 2020: 16 · 2019: 19 · 2018: 14 · 2017: 17 · 2016: 13 · 2015: 16 · 2014: 15 · 2013: 11 · 2012: 9
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01ai015103-024)
- National Institute of Allergy and Infectious Diseases (AI15103, AI65316)
- Topics
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- respiratory syncytial virus, RSV-associated hospitalization, neutralizing antibodies, correlates of immunity, acute respiratory infections, infants and young children, antibody titers, RSV vaccine development
- MeSH terms
- Adolescent, Adult, Age Factors, Antibodies, Viral, Child, Child, Preschool, Female, Hospitalization, Humans, Infant, Male, Nasal Mucosa, Neutralization Tests, Pharynx, Logistic Models, Treatment Outcome, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review